FSMDX
Price
$41.65
Change
+$0.29 (+0.70%)
Updated
Jun 2 closing price
Net Assets
51.53B
JCNRX
Price
$30.29
Change
+$0.62 (+2.09%)
Updated
Jun 2 closing price
Net Assets
4.88B
Interact to see
Advertisement

FSMDX vs JCNRX

Header iconFSMDX vs JCNRX Comparison
Open Charts FSMDX vs JCNRXBanner chart's image
FSMDX vs JCNRX Comparison Chart in %
View a ticker or compare two or three
VS
FSMDX vs. JCNRX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSMDX is a Buy and JCNRX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FSMDX has more cash in the bank: 51.5B vs. JCNRX (4.88B). FSMDX pays higher dividends than JCNRX: FSMDX (0.99) vs JCNRX (0.00). FSMDX was incepted earlier than JCNRX: FSMDX (15 years) vs JCNRX (17 years). JCNRX (1.41) is less costly to investors than FSMDX (0.03). JCNRX is a more actively managed with annual turnover of: 52.00 vs. FSMDX (15.00). FSMDX has a lower initial minimum investment than JCNRX: FSMDX (0) vs JCNRX (2500). FSMDX (22.46) and JCNRX (22.09) have marching annual gain over last year. FSMDX return over 5 years is better than : 42.72 vs. JCNRX (1.44).
FSMDXJCNRXFSMDX / JCNRX
Total Expense Ratio0.031.372%
Annual Report Gross Expense Ratio0.031.412%
Fund Existence15 years17 years-
Gain YTD11.99621.99055%
Front LoadN/AN/A-
Min. Initial Investment02500-
Min. Initial Investment IRAN/AN/A-
Net Assets51.5B4.88B1,054%
Annual Yield % from dividends0.990.00-
Returns for 1 year22.4622.09102%
Returns for 3 years59.3626.58223%
Returns for 5 years42.721.442,967%
Returns for 10 years166.7076.00219%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PUK29.090.28
+0.97%
Prudential PLC
CHEC10.11N/A
N/A
Chenghe Acquisition III Co
SLM22.05-0.01
-0.05%
SLM Corp
CYCN3.02-0.06
-1.95%
Cyclerion Therapeutics
NUTX124.57-3.45
-2.69%
Nutex Health Inc.